Balance Sheet Account Detail (Tables)

12 Months Ended

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Cash and Cash Equivalents and Marketable Securities

The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:

	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated fair Value		Cash and equivalents		Marketable Securities
											Current		Long Term
December 31, 2015
Bank deposits	$	59,625	$	—	$	—	$	59,625	$	59,625	$	—	$	—
Money market funds	80,116		—		—		80,116		80,116		—		—
Bank certificate of deposits	245		—		—		245		—		245		—
Total cash and equivalents and marketable securities	$	139,986	$	—	$	—	$	139,986	$	139,741	$	245	$	—
December 31, 2014
Bank deposits	$	62,997	$	—	$	—	$	62,997	$	62,997	$	—	$	—
Money market funds	66,945		—		—		66,945		66,945		—		—
Bank certificate of deposits	244		—		—		244		—		244		—
Mutual funds	3,062		—		—		3,062		—		3,062		—
Total cash and equivalents and marketable securities	$	133,248	$	—	$	—	$	133,248	$	129,942	$	3,306	$	—

Schedule of Property and Equipment Net of Accumulated Depreciation

“Property and equipment, net of accumulated depreciation” consist of the following:

	December 31,
	2015			2014
Computers hardware and software	$	3,785		$	3,616
Laboratory equipment	608			643
Office furniture	355			344
Leasehold improvements	2,872			2,847
Property and equipment, at cost	7,620			7,450
(Less): Accumulated depreciation	(6,702		)	(6,045		)
Property and equipment, net of accumulated depreciation	$	918		$	1,405

Components of Inventories

“Inventories” consist of the following:

	December 31,
	2015			2014
Raw materials	$	1,606		$	1,507
Work in process*	4,228			3,979
Finished goods	1,498			3,714
(Less:) Non-current portion of inventories included within "other assets" **	$	(3,156	)	$	—
Inventories	$	4,176		$	9,200

*Our work-in-process inventory at December 31, 2015 includes $0.8 million of packaged but unlabeled ZEVALIN vials with expiry in December 2017 (with possible extensions thereafter). In addition to the amounts presented at December 31, 2015, we received $3.4 million of ZEVALIN antibody materials in January 2016 for its future manufacture (representing strategic long-term supply). We expect to sell our existing and committed ZEVALIN inventory over the next few years. However, if our production strategy changes in our transition to a new contract manufacturer, it could result in a charge in that period to “cost of product sales (excludes amortization of intangible assets)” within the Consolidated Statements of Operations.

** The non-current portion of inventories included within "other assets" at December 31, 2015 of $3.2 million, represents inventories we don't expect to sell within the next twelve months based on current estimates.

Summary of Customers Representing 10% or More of Accounts Receivables

A summary of our customers that represent 10% or more of our accounts receivables as of December 31, 2015 and 2014 are as follows:

	Year Ended December 31,
	2015				2014
McKesson Corporation and its affiliates	$	20,281	66.7	%	$	22,534	31.9	%
Cardinal Health, Inc. and its affiliates	7,241		23.8	%	8,432		11.9	%
Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS)	*		—	%	36,154		51.1	%
All other customers	2,862		9.4	%	3,638		5.1	%
Total Accounts Receivables, net	$	30,384	100.0	%	$	70,758	100.0	%

* Less than 10%

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure

“Prepaid expenses and other assets” consist of the following:

	December 31,
	2015		2014
Prepaid operating expenses	$	3,507	$	3,112
2018 Convertible Notes issuance costs (current portion)	699		662
Prepaid expenses and other assets	$	4,206	$	3,774

Schedule of Other Receivables

“Other receivables” consist of the following:

	December 31,
	2015		2014
Income tax receivable	$	1,301	$	1,387
Insurance receivable	7,100		—
Mundipharma promissory note	2,215		—
Research and development expenses - reimbursements due	1,699		4,102
Other miscellaneous receivables	257		—
Other receivables	$	12,572	$	5,489

Components of Intangible Assets Net of Accumulated Amortization

			December 31, 2014
	Historical Cost		Accumulated Amortization			Foreign Currency Translation			Impairment			Net Amount
MARQIBO IPR&D (NHL indications)	$	17,600	$	—		$	—		$	—		$	17,600
EVOMELA IPR&D	7,700		—			—			—			7,700
BELEODAQ distribution rights	25,000		(937		)	—			—			24,063
MARQIBO distribution rights	26,900		(4,225		)	—			—			22,675
FOLOTYN distribution rights	118,400		(20,030		)	—			—			98,370
ZEVALIN distribution rights – U.S.	41,900		(27,134		)	—			—			14,766
ZEVALIN distribution rights – Ex-U.S.	23,490		(7,402		)	(2,162		)	—			13,926
FUSILEV distribution rights	16,778		(6,270		)	—			—			10,508
FOLOTYN out-license	27,900		(6,385		)	—			(1,023		)	20,492
Total intangible assets	$	305,668	$	(72,383	)	$	(2,162	)	$	(1,023	)	$	230,100

“Intangible assets, net of accumulated amortization” consist of the following:

			December 31, 2015
	Historical Cost		Accumulated Amortization				Foreign Currency Translation			Impairment			Net Amount		Full Amortization Period (months)	Remaining Amortization Period (months)
MARQIBO IPR&D (NHL indication)	$	17,600	$	—			$	—		$	—		$	17,600	n/a	n/a
EVOMELA IPR&D	7,700		—				—			—			7,700		n/a	n/a
BELEODAQ distribution rights	25,000		(2,812		)		—			—			22,188		160	142
MARQIBO distribution rights	26,900		(8,544		)		—			—			18,356		81	51
FOLOTYN distribution rights	118,400		(29,474		)		—			—			88,926		152	113
ZEVALIN distribution rights – U.S.	41,900		(30,608		)		—			—			11,292		123	39
ZEVALIN distribution rights – Ex-U.S.	23,490		(12,632		)	***	(4,353		)	—			6,505		96	51
FUSILEV distribution rights*	16,778		(9,618		)		—			(7,160		)	—		56	0
FOLOTYN out-license**	27,900		(9,109		)		—			(1,023		)	17,768		110	79
Total intangible assets	$	305,668	$	(102,797	)		$	(4,353	)	$	(8,183	)	$	190,335

* On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition for the remaining net book value of FUSILEV distribution rights.

** On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million resulted from this amendment.

*** This value is inclusive of $3.7 million of accelerated amortization expense, recorded in the fourth quarter of 2015, which specifically relates to our allocation of the historical cost of certain ZEVALIN ex-U.S. rights out-licensed to Mundipharma (see Note 12) at that time.

Estimated Intangible Asset Amortization Expense

Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:

Years Ending December 31
2016	$	23,360
2017	23,368
2018	23,368
2019	20,762
2020	15,505
2021 and thereafter	58,672
	$	165,035

Schedule of Goodwill

“Goodwill” is comprised of the following:

	December 31,
	2015			2014
Acquisition of Talon	$	10,526		$	10,526
Acquisition of ZEVALIN Ex-U.S. distribution rights	2,525			2,525
Acquisition of Allos	5,346			5,346
Foreign currency exchange translation effects	(437		)	(202		)
Goodwill	$	17,960		$	18,195

Summary of Other Assets

“Other assets” are comprised of the following:

	December 31,
	2015		2014
Equity securities and secured promissory note (see Note 11)*	$	6,689	$	8,501
Supplies and deposits	185		234
2018 Convertible Notes issuance costs (excluding current portion)**	1,472		2,171
Executive officer life insurance – cash surrender value	9,181		6,958
Inventories - non-current portion	$	3,156	$	—
Other assets	$	20,683	$	17,864

* These equity securities were excluded from “marketable securities” (see Note 3(a)) due to our intent to hold these securities for at least one year beyond December 31, 2015, as discussed in Note 11. Unrealized losses from these equity securities were recognized through “unrealized (loss) gain on available-for-sale securities" within the Consolidated Statements of Comprehensive Loss, and were $1.4 million for the year ended December 31, 2015.

** In April 2015, the FASB issued Accounting Standards Update 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. However, ASU 2015-03 does not impact the recognition and measurement guidance for debt issuance costs. ASU 2015-03 is effective for our annual and interim reporting periods beginning January 1, 2016. Accordingly, we will record a reclassification of our 2018 Convertible Notes issuance costs, from “other assets” to “convertible senior notes” within our Consolidated Balance Sheets, beginning January 1, 2016.

Schedule of Accounts Payable and Other Accrued Obligations

Accounts payable and other accrued obligations are comprised of the following:

	December 31,
	2015		2014
Trade accounts payable and other accrueds	$	26,684	$	24,571
Accrued rebates	18,166		41,782
Accrued product royalty	4,908		5,182
Allowance for returns	1,394		1,135
Accrued data and distribution fees	1,830		3,952
Accrued GPO administrative fees	1,058		3,222
Inventory management fee	498		1,110
Allowance for chargebacks	2,001		4,040
Accounts payable and other accrueds	$	56,539	$	84,994

Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

Description	Rebates and Chargebacks			Data and Distribution, GPO Fees, and Inventory Management Fees			Returns
Balance as of December 31, 2013	$	33,967		$	5,373		$	2,900
Add: provisions (recovery)	76,636			21,330			(78		)
(Less): credits or actual allowances	(64,781		)	(18,419		)	(1,687		)
Balance as of December 31, 2014	45,822			8,284			1,135
Add: provisions	75,498			15,928			1,486
(Less): credits or actual allowances	(101,153		)	(20,826		)	(1,227		)
Balance as of December 31, 2015	$	20,167		$	3,386		$	1,394

Deferred Revenue, by Arrangement, Disclosure

Deferred revenue (including current and long-term) is comprised of the following:

	December 31,
	2015		2014
CASI out-license (see Note 11)	$	—	$	9,959
FUSILEV deferred revenue*	6,083		—
Dr. Reddy's out-license (see Note 17(b)(iii))	430		—
Deferred revenue	$	6,513	$	9,959

* During the third quarter 2015, we deferred revenue recognition related to certain FUSILEV product shipments that did not meet our revenue recognition criteria (see Note 2(i)(a)), aggregating $9.9 million. Specifically, this deferral is a result of our inability to estimate future rebate values (with requisite precision) offered to our customers in order to compete with generic products. During the fourth quarter of 2015, we recognized $3.8 million for these third quarter shipments within "Product sales, net." As of December 31, 2015, $6.1 million of these third quarter 2015 shipments remains deferred.

Summary of Other Long-Term Liabilities

Other long-term liabilities are comprised of the following:

	December 31,
	2015		2014
Accrued executive deferred compensation	$	6,458	$	4,694
Deferred rent (non-current portion)	248		364
Business acquisition liability	—		300
Other tax liabilities	738		730
Other long-term liabilities	$	7,444	$	6,088